While a small number of Ozempic users report suicidal thoughts, clinical trials haven’t found an increased risk.
The family of Anthony, who died by suicide in May after starting Ozempic to manage his Type 2 diabetes, is calling for a warning about suicidal thoughts to be added to the drug’s label. They believe the medication contributed to his tragic death, noting that his once upbeat personality shifted to fatigue and silence after starting the treatment. Although Ozempic and its sister drug, Wegovy, have seen a surge in popularity, a small number of users—some with a history of depression—have reported experiencing suicidal ideation, prompting safety reviews by regulatory agencies such as the European Medicines Agency and the U.S. Food and Drug Administration (FDA).
The FDA has received reports of suicidal thoughts related to Ozempic, but the numbers are relatively small compared to the widespread use of the drug. Clinical trials have not shown a direct connection between Ozempic and suicidal ideation, and three doctors who prescribe the drug reported no noticeable link. Despite this, the family believes the drug should carry a warning similar to Wegovy, which is used for weight loss and already carries a warning about suicidal thoughts.
Novo Nordisk, the manufacturer of both drugs, maintains that the evidence does not suggest a higher risk of suicide or self-injury with Ozempic. The company continues to work with regulatory agencies to ensure the drug’s label accurately reflects its safety profile.
